Znn3bq.jpeg
²é¿´: 931  |  »Ø¸´: 2
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

chenlinana

Í­³æ (³õÈëÎÄ̳)

[ÇóÖú] ÇëÎʸßÊÖÕâ¾ä»°ÖÐtreat and extend regimenÓ¦¸ÃÔõô·­Ò룿

To evaluate the visual outcome, number of injections, and direct medical cost of a "treat and extend regimen (TER) in managing neovascular age-related macular degeneration (nAMD) with intravitreal ranibizumab.
ÇëÎʸßÊÖÕâ¾ä»°ÖÐtreat and extend regimenÓ¦¸ÃÔõô·­Ò룿

» ²ÂÄãϲ»¶

Î¢Ð¦Ãæ¶ÔÿһÌì
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

xux730

Ìú¸Ëľ³æ (ÖøÃûдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï
RXMCDM: ½ð±Ò+1, ¶àлӦÖú£¡ 2014-08-03 20:59:03
chenlinana(RXMCDM´ú·¢): ½ð±Ò+4, ¶àлӦÖú£¡ 2014-08-12 09:16:19
ÖÎÁƺÍÑÓÉì·½°¸£º³õ²½ÖÎÁƺó¼ÌÐø¸øÒ©£¬µ«ÊǸøÒ©µÄ¼äÆÚÖð½¥ÑÓ³¤¡£
3Â¥2014-08-01 02:56:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 3 ¸ö»Ø´ð

RXMCDM

°æÖ÷ (ÎÄ̳¾«Ó¢)

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÕÒµ½ÄÜ˵Ã÷Õâ¸ö´ÊµÄÎÄ×ÖÈçÏ£¬¾õµÃ¿ÉÒÔÃãÇ¿·­Îª¡¡¡¡ÖÎÁƼÁÁ¿¼°ÖÎÁƺóµÍƵ¸øÒ©¡¡¡¡¹©Äã²Î¿¼£¡
TREAT AND EXTEND¡± DOSING OF INTRAVITREAL ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR TYPE 3 NEOVASCULARIZATION/RETINAL ANGIOMATOUS PROLIFERATION
Purpose: The purpose of this study was to analyze long-term outcomes for the treatment of type 3 neovascularization/retinal angiomatous proliferation using a ¡°Treat and Extend¡± dosing regimen for antivascular endothelial growth factor therapy.
Methods: This was a retrospective analysis of visual acuity and optical coherence tomography data of 11 eyes of 10 consecutive patients with newly diagnosed type 3 neovascularization/retinal angiomatous proliferation treated with intravitreal bevacizumab and/or ranibizumab with at least a 12-month follow-up. Three monthly injections were followed by continued treatment at intervals increasing by 2 weeks per visit, to a maximum of 10 weeks, unless clinical or optical coherence tomography evidence of persistent or recurrent fluid was present, in which case, the interval was shortened.
£¿
2Â¥2014-08-01 00:17:24
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] »¯Ñ§¹¤³Ìµ÷¼Á289 +41 yangæÃ 2026-04-07 47/2350 2026-04-09 23:23 by wolf97
[¿¼ÑÐ] 297Çóµ÷¼Á +8 Kwgyz 2026-04-09 8/400 2026-04-09 23:22 by may_ÐÂÓî
[¿¼ÑÐ] ²ÄÁϸ´ÊÔÇóµ÷¼Á +16 xhhdjdjsjks 2026-04-09 16/800 2026-04-09 20:56 by bljnqdcc
[¿¼ÑÐ] 086003µ÷¼ÁÇóÖú +19 ËÕß®Íò 2026-04-09 20/1000 2026-04-09 20:48 by bljnqdcc
[¿¼ÑÐ] ¿¼Ñе÷¼Á-²ÄÁÏÀà-284 +28 Ïë»»ÊÖ»ú²»Ïë½âÊ 2026-04-08 28/1400 2026-04-09 20:08 by µ¹Êý321?
[¿¼ÑÐ] Ò»Ö¾Ô¸085404£¬×Ü·Ö291£¬Ëļ¶Òѹý£¬Çóµ÷¼Á +10 °¢¿¡°¢¿¡°¢¿¡ 2026-04-04 12/600 2026-04-09 16:18 by lin-da
[¿¼ÑÐ] 274Çóµ÷¼Á +5 ɽ°¢Âû 2026-04-07 5/250 2026-04-09 15:28 by 18828373951
[¿¼ÑÐ] 085600£¬321·ÖÇóµ÷¼Á +19 ´ó²öС×Ó 2026-04-04 20/1000 2026-04-09 14:12 by Delta2012
[¿¼ÑÐ] 085801 ×Ü·Ö275 ±¾¿ÆÐÂÄÜÔ´ Çóµ÷¼Á +8 bradoner 2026-04-08 9/450 2026-04-09 13:43 by onlyÖÜ
[¿¼ÑÐ] ±¾¿ÆÄÏ·½Ò½¿Æ´óѧ Ò»Ö¾Ô¸985 ҩѧѧ˶284·Ö Çóµ÷¼Á +3 ÈõË®ÌýÎÄ 2026-04-09 3/150 2026-04-09 09:06 by susuqq
[¿¼²©] ²ÄÁÏ·½Ïò¿¼²©£¬ÇóÍÆ¼ö +3 ÑÔÓïaaa 2026-04-05 4/200 2026-04-08 22:22 by nxgogo
[¿¼ÑÐ] 331Çóµ÷¼Á +5 luoxin0706. 2026-04-08 5/250 2026-04-08 22:15 by zhouyuwinner
[¿¼ÑÐ] ¼ÆËã»ú408£üÔÚУ¶à´Î¹ú¼Ò¼¶¾ºÈü»ñ½±£üÉêÇëµ÷¼Á +4 ¶«É½´ó°×¶ì 2026-04-05 4/200 2026-04-08 00:18 by chongya
[¿¼ÑÐ] 307Çóµ÷¼Á +3 Youth@@ 2026-04-07 3/150 2026-04-07 22:00 by hemengdong
[¿¼ÑÐ] 085602µ÷¼Á ³õÊÔ×Ü·Ö335 +3 19123253302 2026-04-06 3/150 2026-04-07 18:00 by jp9609
[¿¼ÑÐ] 372·Ö²ÄÁÏÓ뻯¹¤£¨085600£©Ó¢¶þÊý¶þÇóµ÷¼Á +4 À¶¼ãƬ 2026-04-06 4/200 2026-04-07 12:30 by dongzh2009
[¿¼ÑÐ] 334·Ö¿ØÖƹ¤³ÌÇóµ÷¼Á +4 ½ªÉÐÕæsadasd 2026-04-03 4/200 2026-04-07 09:26 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Äܶ¯µ÷¼Á326ר˶ +4 wan112233 2026-04-04 4/200 2026-04-04 22:47 by yu221
[¿¼ÑÐ] 0835ѧ˶299Çóµ÷¼Á 08´óÀà¿É½ÓÊÜ +5 useryy 2026-04-03 5/250 2026-04-04 20:07 by À¶ÔÆË¼Óê
[¿¼ÑÐ] Ò»Ö¾Ô¸±±½»´ó²ÄÁϹ¤³Ì×Ü·Ö358 +6 cs0106 2026-04-03 6/300 2026-04-04 11:20 by w_xuqing
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û